A Multi-Site Open-Label Safety Extension Study of Manualized MDMA-Assisted Psychotherapy for the Treatment of Participants With Posttraumatic Stress Disorder
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Methylenedioxymetamfetamine (Primary)
- Indications Post-traumatic stress disorders
- Focus Registrational; Therapeutic Use
- Acronyms MAPPUSX
- Sponsors Lykos Therapeutics
- 06 Dec 2023 Status changed from active, no longer recruiting to completed.
- 19 Sep 2023 Planned End Date changed from 13 Aug 2023 to 31 Oct 2024.
- 19 Sep 2023 Planned primary completion date changed from 13 Aug 2023 to 31 Oct 2024.